Neuland Laboratories Ltd vs Themis Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Neuland Laboratories Ltd is ₹ 17177 as of 12 Jun 15:30 . The P/E Ratio of Neuland Laboratories Ltd changed from 33.4 on March 2021 to 59.9 on March 2025 . This represents a CAGR of 12.39% over 5 yearsThe P/E Ratio of Themis Medicare Ltd changed from 7.2 on March 2021 to 45.3 on March 2025 . This represents a CAGR of 44.46% over 5 years The Market Cap of Neuland Laboratories Ltd changed from ₹ 2678 crore on March 2021 to ₹ 15494 crore on March 2025 . This represents a CAGR of 42.05% over 5 yearsThe Market Cap of Themis Medicare Ltd changed from ₹ 257.55 crore on March 2021 to ₹ 1349 crore on March 2025 . This represents a CAGR of 39.28% over 5 years The revenue of Neuland Laboratories Ltd for the Mar '26 is ₹ 788.71 crore as compare to the Dec '25 revenue of ₹ 447.76 crore. This represent the growth of 76.15% The revenue of Themis Medicare Ltd for the Mar '26 is ₹ 87.13 crore as compare to the Dec '25 revenue of ₹ 96.93 crore. This represent the decline of -10.11% The ebitda of Neuland Laboratories Ltd for the Mar '26 is ₹ 319.79 crore as compare to the Dec '25 ebitda of ₹ 85.19 crore. This represent the growth of 275.38% The ebitda of Themis Medicare Ltd for the Mar '26 is ₹ 14.36 crore as compare to the Dec '25 ebitda of ₹ 15.73 crore. This represent the decline of -8.71% The net profit of Neuland Laboratories Ltd changed from ₹ 97.87 crore to ₹ 212.67 crore over 8 quarters. This represents a CAGR of 47.41% The net profit of Themis Medicare Ltd changed from ₹ 24.68 crore to ₹ 8.89 crore over 8 quarters. This represents a CAGR of -39.98% The Dividend Payout of Neuland Laboratories Ltd changed from 8.03 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of -5.76% over 5 yearsThe Dividend Payout of Themis Medicare Ltd changed from 14.84 % on March 2021 to 19.23 % on March 2025 . This represents a CAGR of 5.32% over 5 years .

About Neuland Laboratories Ltd

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin.
Neuland Drugs & Pharmaceuticals Pvt.
Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

About Themis Medicare Ltd

Themis Medicare Limited was formerly incorporated as 'Themis Chemicals Limited' in 1969.
The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993.
Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001.
The Company is principally engaged in the business of manufacturing of finished formulations and synthetic Active Pharmaceutical Ingredients. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.

FAQs for the comparison of Neuland Laboratories Ltd and Themis Medicare Ltd

Which company has a larger market capitalization, Neuland Laboratories Ltd or Themis Medicare Ltd?

Market cap of Neuland Laboratories Ltd is 22,038 Cr while Market cap of Themis Medicare Ltd is 960 Cr

What are the key factors driving the stock performance of Neuland Laboratories Ltd and Themis Medicare Ltd?

The stock performance of Neuland Laboratories Ltd and Themis Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Neuland Laboratories Ltd and Themis Medicare Ltd?

As of June 15, 2026, the Neuland Laboratories Ltd stock price is INR ₹17177.5. On the other hand, Themis Medicare Ltd stock price is INR ₹104.25.

How do dividend payouts of Neuland Laboratories Ltd and Themis Medicare Ltd compare?

To compare the dividend payouts of Neuland Laboratories Ltd and Themis Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.